Immunometabolism of Age-Related Frailty: Mechanisms, Clinical Insights, and Emerging Therapeutic Strategies

Abstract

Age-related frailty is an increasingly recognized geriatric syndrome characterized by diminished physiological reserves, multisystem impairment, and increased vulnerability to stressors. Recent advances underscore the central role of immunometabolism interactions between immune function and metabolic processes in the pathogenesis and progression of frailty. This review synthesizes the epidemiological trends, pathophysiological underpinnings, clinical features, diagnostic approaches, and therapeutic strategies for frailty with a focus on immunometabolic mechanisms. Emphasis is placed on recent evidence, emerging therapies targeting immunometabolic pathways, and practical clinical implications for healthcare professionals managing older adults.

Introduction

Frailty in older adults represents a state of heightened susceptibility to adverse health outcomes, including falls, disability, hospitalization, and mortality. Traditionally viewed through the lens of sarcopenia and physical decline, recent scientific consensus has shifted towards a multidimensional model incorporating immune and metabolic dysfunction. Immunometabolism the bidirectional relationship between immune cell activity and metabolic pathways has emerged as a key driver of chronic inflammation, mitochondrial dysfunction, and impaired tissue repair in frailty. Understanding these mechanisms is critical for developing targeted interventions and improving clinical outcomes in geriatric populations.

Epidemiology / Disease Burden

Frailty affects approximately 10-15% of community-dwelling adults over 65 years, with prevalence rising to over 40% in institutionalized elderly populations. The syndrome is associated with substantial healthcare utilization and costs due to increased rates of hospitalization, prolonged recovery, and higher incidence of complications such as infections and delirium. Epidemiological studies consistently demonstrate a higher burden of frailty among women, individuals with multiple comorbidities, and those of lower socioeconomic status. The global demographic shift towards an aging population magnifies the clinical and public health significance of frailty, underscoring the need for effective prevention and management strategies grounded in an understanding of underlying pathophysiology.

Pathophysiology

The pathogenesis of age-related frailty is multifactorial, with immunometabolic dysregulation playing a pivotal role. Immunosenescence age-associated decline in adaptive immunity is characterized by reduced T-cell repertoire diversity, impaired B-cell function, and chronic activation of innate immune pathways. Concurrently, metabolic alterations such as insulin resistance, mitochondrial dysfunction, and impaired oxidative phosphorylation compromise cellular energy homeostasis. These changes collectively foster a pro-inflammatory milieu, often termed "inflammaging," marked by elevated circulating cytokines (e.g., IL-6, TNF-α, CRP). Mitochondrial dysfunction in immune cells impairs their ability to respond to pathogens and resolve inflammation, perpetuating tissue damage and functional decline. Furthermore, alterations in nutrient sensing pathways (e.g., mTOR, AMPK, SIRT1) modulate immune cell metabolism and contribute to the frail phenotype.

Risk Factors

Risk factors for age-related frailty include advanced age, female sex, chronic comorbidities (cardiovascular disease, diabetes, chronic kidney disease), physical inactivity, malnutrition, cognitive impairment, and polypharmacy. Genetic predispositions influencing immune and metabolic pathways, such as polymorphisms in inflammatory cytokine genes, may also contribute. Lifestyle factors, including poor diet quality and sedentary behavior, exacerbate metabolic dysfunction and immune senescence. Additionally, psychosocial determinants such as social isolation and depression are increasingly recognized as contributors via stress-induced dysregulation of immune and metabolic homeostasis.

Clinical Features

Clinically, frailty manifests as unintentional weight loss, muscle weakness, exhaustion, slow gait speed, and low physical activity. Patients often present with increased susceptibility to infections, delayed recovery from illness, and exacerbation of chronic diseases. Immunometabolic dysfunction may also contribute to atypical presentations such as blunted fever response or prolonged convalescence following acute illness. Cognitive decline and mood disturbances frequently coexist, compounding functional impairment and complicating clinical management.

Diagnosis

Diagnosis of frailty relies on validated screening tools such as the Fried Frailty Phenotype (assessing weight loss, grip strength, exhaustion, gait speed, and activity level) and the Frailty Index (quantifying deficits across multiple domains). Laboratory markers reflecting immunometabolic dysfunction such as elevated inflammatory cytokines, reduced lymphocyte counts, and metabolic biomarkers (e.g., fasting glucose, albumin, vitamin D) may provide adjunctive information but are not yet routinely incorporated into diagnostic algorithms. Emerging research supports the use of composite biomarker panels to improve risk stratification and guide personalized interventions.

Treatment & Management

Management of frailty is multifaceted, emphasizing both non-pharmacological and pharmacological strategies. Exercise programs particularly those combining resistance and aerobic training are effective in improving muscle strength, physical function, and metabolic health. Nutritional interventions, including protein supplementation, vitamin D repletion, and correction of micronutrient deficiencies, support immune and metabolic resilience. Comprehensive geriatric assessment is essential to identify and address contributing factors such as polypharmacy, comorbidities, and psychosocial stressors. Pharmacological approaches targeting immunometabolic pathways (e.g., anti-inflammatory agents, glucose-lowering medications) are being explored, but evidence for routine use remains limited. Multidisciplinary care models involving geriatricians, nutritionists, physiotherapists, and social workers are recommended for optimal outcomes.

Recent Advances / Emerging Therapies

Recent research has identified several promising avenues for therapeutic intervention. Agents modulating mTOR signaling (e.g., rapalogs) have shown potential in enhancing immune function and reducing inflammation in preclinical and early-phase clinical studies. Senolytic drugs targeting senescent cells may alleviate chronic inflammation and improve tissue repair. Mitochondrial-targeted antioxidants and metabolic modulators (e.g., NAD+ precursors) are under investigation for their capacity to restore cellular energy balance and enhance immune cell function. Personalized medicine approaches utilizing multi-omics profiling and machine learning algorithms are being developed to predict frailty risk and tailor interventions based on individual immunometabolic profiles.

Guideline Recommendations

International guidelines, including those from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Association of Gerontology and Geriatrics (IAGG), emphasize routine frailty screening in older adults and advocate for multi-component interventions addressing physical, nutritional, and psychosocial domains. The integration of immunometabolic assessment into clinical practice is encouraged, particularly in research and specialized geriatric care settings. Guidelines highlight the importance of exercise, adequate nutrition, and management of comorbidities, with emerging recommendations for the use of targeted pharmacologic and biologic therapies as evidence evolves.

Conclusion

Immunometabolic dysregulation is central to the development and progression of age-related frailty, underpinning a complex interplay between chronic inflammation, metabolic dysfunction, and multisystem decline. Advances in our understanding of these mechanisms provide a foundation for novel diagnostic and therapeutic strategies aimed at mitigating frailty and its adverse outcomes. Clinicians should incorporate immunometabolic considerations into frailty assessment and management, leveraging multidisciplinary approaches and emerging evidence to optimize care for the aging population.